Abiopharma

🔍 Greylock XIV GP LLC (Executive)

Company: Figma, Inc. (FIG)

Report Date: 2026-08-07

Detailed Transactions and Holdings:

• Sold 13,144,577 shares of Class A Common Stock (Direct)
  Date: 2026-08-07 | Code: J | equity_swap_involved: false | shares_owned_after: 39,433,730.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 730,257 shares of Class A Common Stock (Direct)
  Date: 2026-08-07 | Code: J | equity_swap_involved: false | shares_owned_after: 2,190,772.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 730,257 shares of Class A Common Stock (Direct)
  Date: 2026-08-07 | Code: J | equity_swap_involved: false | shares_owned_after: 2,190,772.00 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: Represents a pro-rata, in-kind distribution by the Reporting Person and its affiliated funds and associated persons, without additional consideration, to its respective partners, members and/or assigns. Such distribution was made in accordance with the exemption afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.
• F2: Greylock XIV GP LLC ("Greylock XIV GP") is the sole general partner of each of Greylock XIV Limited Partnership ("Greylock XIV") and Greylock XIV-A Limited Partnership ("Greylock XIV-A") and manager of Greylock XIV Principals LLC ("Greylock XIV Principals") and may be deemed to share voting and dispositive power with respect to the shares held directly by Greylock XIV, Greylock XIV-A and Greylock XIV Principals. Greylock XIV GP disclaims beneficial ownership of the securities held by Greylock XIV, Greylock XIV-A and Greylock XIV Principals, except to the extent of any pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission by Greylock XIV GP of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.